CAPTRUST Financial Advisors
PLX icon

CAPTRUST Financial Advisors’s Protalix BioTherapeutics PLX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$1K – 3504
2022
Q2 		$1K Hold
800
– – ﹤0.01% 4720
2022
Q1 		$1K Hold
800
– – ﹤0.01% 4728
2021
Q4 		$1K Hold
800
– – ﹤0.01% 4615
2021
Q3 		$1K Hold
800
– – ﹤0.01% 4469
2021
Q2 		$2K Hold
800
– – ﹤0.01% 4197
2021
Q1 		$4K Buy
+800
New +$3.73K ﹤0.01% 3815

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CPA
Capital Performance Advisors Walnut Creek, California $1.5B AUM 21.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CAPTRUST Financial Advisors's PLX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2022, closing a stake of 800 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in PLX in Q1 2021 and held it in 6 quarters. The position peaked at $4K in Q1 2021. 27 funds tracked by Wall St. Rank hold PLX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 800 Protalix BioTherapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's Protalix BioTherapeutics position peaked at $4K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.